Related Experiment Video
Updated: Dec 29, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Bleeding Tolerance Among Patients With Atrial Fibrillation on Oral Anticoagulation
Gabriela Rusin1, Małgorzata Konieczyńska2, Piotr Bijak2
1Department of Neurology, Jagiellonian University Medical College, Kraków, Poland.
Insights
Older age and previous bleeding or stroke events significantly influence how many bleeds patients with atrial fibrillation (AF) will accept while on oral anticoagulation therapy. AF knowledge level did not impact this acceptance.
Area of Science:
- Cardiology
- Internal Medicine
- Thrombosis Management
Background:
- Oral anticoagulation is crucial for preventing stroke in atrial fibrillation (AF) but increases bleeding risk.
- Patient acceptance of this therapy is influenced by their perception of bleeding risk versus stroke prevention.
- Understanding factors affecting bleeding acceptance is vital for long-term treatment adherence.
Purpose of the Study:
- To investigate the impact of clinical factors and atrial fibrillation (AF) knowledge on bleeding acceptance in anticoagulated AF patients.
- To identify patient characteristics associated with a lower tolerance for bleeding events during anticoagulation.
Main Methods:
- 173 consecutive anticoagulated AF outpatients were assessed for their 'bleeding ratio' – the number of major bleeds they would tolerate to prevent one stroke.
- The Jessa AF Knowledge Questionnaire was used to evaluate patients' understanding of AF.
- Statistical analysis identified independent predictors of a low bleeding ratio.
Main Results:
- Older age, longer AF duration, heart failure, and prior cerebrovascular events were associated with a lower bleeding ratio.
- Patients with a history of major or minor bleeds on anticoagulation had a significantly lower bleeding ratio.
- The level of AF knowledge did not significantly affect the bleeding ratio.
Conclusions:
- Age and a history of thromboembolic or bleeding events are key determinants of bleeding acceptance in anticoagulated AF patients.
- These findings can help identify AF patients who may require additional support to improve acceptance of long-term oral anticoagulation therapy.
Background:
Oral anticoagulation increases the bleeding risk. We investigated how clinical factors and the level of atrial fibrillation (AF) knowledge affect the bleeding acceptance in patients with AF.
Methods:
In 173 consecutive anticoagulated outpatients with AF (aged 68.7 ± 10.7 years, 39.3% male), the bleeding ratio was assessed based on the declared maximum number of major bleeds the people were willing to endure to avert 1 stroke. The Jessa AF Knowledge Questionnaire was used to assess the knowledge of AF.
Results:
Compared with patients with the high bleeding ratio (≥ 4 accepted bleedings, n = 88, 50.9%), subjects with the low bleeding ratio (0-3 accepted bleedings, n = 85, 49.1%) were older, with longer duration of AF, suffered more commonly from heart failure, and were free of cerebrovascular events. Patients after major bleeding (n = 33, 19.1%) and those reporting minor bleeds on anticoagulation (n = 77, 44.5%) had lower bleeding ratio. The independent predictors of the low bleeding ratio were older age (odds ratio [OR], 2.50; 95% confidence interval [CI], 1.69-3.70), major bleeds on anticoagulation (OR, 3.33; 95% CI, 1.16-10.0), minor bleeds on anticoagulation (OR, 3.45; 95% CI, 1.67-7.14), and prior stroke/transient ischemic attack (OR, 0.47; 95% CI, 0.22-0.99). The level of knowledge of AF did not affect the bleeding ratio.
Conclusions:
The key determinants of the bleeding ratio among anticoagulated patients with AF are age, and prior thromboembolic and bleeding episodes. The study could support identification of patients with AF who need additional effort to increase their acceptance of a life-long oral anticoagulation therapy.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis IV: Nursing Management
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

